14,353 Shares in Harrow, Inc. $HROW Purchased by Grandeur Peak Global Advisors LLC

Grandeur Peak Global Advisors LLC purchased a new stake in shares of Harrow, Inc. (NASDAQ:HROW) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,353 shares of the company’s stock, valued at approximately $610,000.

Several other large investors have also recently bought and sold shares of HROW. University of Texas Texas AM Investment Management Co. bought a new position in Harrow in the fourth quarter valued at approximately $26,000. KBC Group NV bought a new stake in shares of Harrow during the 1st quarter worth approximately $31,000. SBI Securities Co. Ltd. raised its stake in shares of Harrow by 393.5% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock worth $52,000 after purchasing an additional 846 shares in the last quarter. First Bancorp Inc ME acquired a new stake in shares of Harrow in the 2nd quarter valued at approximately $64,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Harrow in the 2nd quarter valued at approximately $48,000. 72.76% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on HROW. Cantor Fitzgerald lowered their target price on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Wall Street Zen upgraded shares of Harrow from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research report on Monday, July 20th. BTIG Research restated a “buy” rating and set a $63.00 price objective on shares of Harrow in a research note on Tuesday, August 11th. Finally, Zacks Research lowered shares of Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 11th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Harrow presently has an average rating of “Moderate Buy” and a consensus price target of $69.43.

Harrow Stock Performance

HROW opened at $37.27 on Monday. The company has a quick ratio of 2.08, a current ratio of 2.24 and a debt-to-equity ratio of 19.70. Harrow, Inc. has a 12-month low of $28.54 and a 12-month high of $54.85. The business has a 50 day moving average of $41.28 and a 200-day moving average of $39.51. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -37.27 and a beta of 0.28.

Harrow (NASDAQ:HROW) last posted its earnings results on Monday, August 10th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.28). Harrow had a negative return on equity of 38.00% and a negative net margin of 13.51%.The business had revenue of $70.66 million for the quarter, compared to analyst estimates of $70.35 million.

Insider Buying and Selling

In other Harrow news, insider Amir Shojaei sold 11,250 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $40.00, for a total value of $450,000.00. Following the transaction, the insider directly owned 11,250 shares in the company, valued at $450,000. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 12.80% of the stock is currently owned by company insiders.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.